Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.
– Each shareholder is estimated to receive US$1.82 per share plus one CVR per common share – – Transaction expected to close in the first quarter of 2026 – – Additional portfolio monetization efforts continue – – Company reports 3Q 2025 financial results – –
(Financial Post, 2025-11-14T21:46:26Z)